Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults greater than or equal to 50 years with underlying chronic medical conditions

Invasive pneumococcal diseases (IPD) are associated with substantial burden in adults ( greater than or equal to 50 years). Moreover, adults with vascular, metabolic or respiratory diseases have been shown to have a 3-6 times higher risk of IPD when compared with their healthy controls. These persons at higher risk are likely to benefit most from pneumococcal vaccinations. The 13-valent pneumococcal conjugate vaccine (PCV13) was recently introduced to prevent the 13 most prevalent serotypes causing invasive pneumococcal disease in adults. The objective of this study was to estimate the expected 5-year economic impact of targeted PCV13 vaccination compared with no vaccination in Finnish adults ( greater than or equal to 50 years) at moderate or high risk for IPD. A budget impact model was developed to predict the impact of PCV13 vaccination in terms of the costs and IPD events avoided for years 2012-2016. Approximately 35% of the 2.2 million Finns over 50 years of age can be considered to be at moderate or high risk for IPD because of underlying chronic medical conditions. Vaccination of these people with PCV13 could provide an estimated net budget savings of about [Euro218 million compared with the current no-vaccination situation over the next 5 years. Among the risk groups considered, the largest absolute net savings ([Euro66.2 million) could be expected to be obtained by vaccinating people with heart disease, due to its high prevalence in the target population. In Finland, the immunization with PCV13 vaccine, of adults ( greater than or equal to 50 years) at moderate and high risk of IPD, is estimated to lead to substantial cost savings in the 5 years after vaccination.